0001209191-20-025342.txt : 20200422 0001209191-20-025342.hdr.sgml : 20200422 20200422161455 ACCESSION NUMBER: 0001209191-20-025342 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200420 FILED AS OF DATE: 20200422 DATE AS OF CHANGE: 20200422 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Yuchun CENTRAL INDEX KEY: 0001334365 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20808086 MAIL ADDRESS: STREET 1: 170 TRACER LA. CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-20 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001334365 Lee Yuchun C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 Common Stock 2020-04-20 4 M 0 2000 57.27 A 3875 D Common Stock 2020-04-20 4 S 0 100 269.97 D 3775 D Common Stock 2020-04-20 4 S 0 510 271.52 D 3265 D Common Stock 2020-04-20 4 S 0 890 273.61 D 2375 D Common Stock 2020-04-20 4 S 0 500 274.65 D 1875 D Common Stock 2020-04-21 4 M 0 2000 57.27 A 3875 D Common Stock 2020-04-21 4 S 0 297 263.20 D 3578 D Common Stock 2020-04-21 4 S 0 500 264.80 D 3078 D Common Stock 2020-04-21 4 S 0 300 265.88 D 2778 D Common Stock 2020-04-21 4 S 0 403 267.15 D 2375 D Common Stock 2020-04-21 4 S 0 100 268.50 D 2275 D Common Stock 2020-04-21 4 S 0 300 271.38 D 1975 D Common Stock 2020-04-21 4 S 0 100 272.63 D 1875 D Stock Option (Right to Buy) 57.27 2020-04-20 4 M 0 2000 0.00 D 2022-09-13 Common Stock 2000 11125 D Stock Option (Right to Buy) 57.27 2020-04-21 4 M 0 2000 0.00 D 2022-09-13 Common Stock 2000 9125 D Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $271.52 (range $271.04 to $271.98). Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $273.61 (range $273.20 to $274.03). Open market sales reported on this line occurred at a weighted average price of $274.65 (range $274.37 to $275.32). Open market sales reported on this line occurred at a weighted average price of $263.20 (range $262.68 to $263.65). Open market sales reported on this line occurred at a weighted average price of $264.80 (range $264.33 to $265.14). Open market sales reported on this line occurred at a weighted average price of $265.88 (range $265.45 to $266.33). Open market sales reported on this line occurred at a weighted average price of $267.15 (range $266.85 to $267.47). Open market sales reported on this line occurred at a weighted average price of $271.38 (range $271.12 to $271.69). Fully vested. /s/ Omar White, Attorney-in-Fact 2020-04-22